Literature DB >> 9783332

Pharmacokinetics and oral bioavailability of glycopyrrolate in children.

P Rautakorpi1, T Manner, T Ali-Melkkilä, T Kaila, K Olkkola, J Kanto.   

Abstract

Based on plasma levels determined with a radioreceptor assay and following a single oral (50 micrograms/kg) and intravenous (5 micrograms/kg) administration of glycopyrrolate in six healthy children operated twice during a several weeks period, a negligible and variable oral bioavailability was found (3.3; 1.3-13.3%) (median;range). No significant changes in heart rate after oral or intravenous administration of the drug could be seen. Oral glycopyrrolate appears to have no place in paediatric premedication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9783332     DOI: 10.1111/j.1600-0773.1998.tb01456.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  6 in total

1.  Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.

Authors:  Christian Bartels; Michael Looby; Romain Sechaud; Guenther Kaiser
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

2.  Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditions.

Authors:  Robert S Zeller; Jennifer Davidson; Hak-Myung Lee; Paul F Cavanaugh
Journal:  Ther Clin Risk Manag       Date:  2012-01-25       Impact factor: 2.423

3.  Randomized Phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions.

Authors:  Robert S Zeller; Hak-Myung Lee; Paul F Cavanaugh; Jennifer Davidson
Journal:  Ther Clin Risk Manag       Date:  2012-01-25       Impact factor: 2.423

4.  Iontophoretic and microneedle mediated transdermal delivery of glycopyrrolate.

Authors:  Meera Gujjar; Ajay K Banga
Journal:  Pharmaceutics       Date:  2014-12-22       Impact factor: 6.321

5.  A case report: Glycopyrrolate for treatment of exercise-induced hyperhidrosis.

Authors:  Matthew Negaard; Christopher Anthony; Daniel Bonthius; Matthew Jepson; Britt Marcussen; Daniel Pelzer; Andrew Peterson
Journal:  SAGE Open Med Case Rep       Date:  2017-08-08

6.  Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.

Authors:  Adelaide A Hebert; Dee Anna Glaser; Lawrence Green; William P Werschler; Douglass W Forsha; Janice Drew; Ramanan Gopalan; David M Pariser
Journal:  Pediatr Dermatol       Date:  2018-11-19       Impact factor: 1.588

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.